Shots:

• Curadev to receive upfront- research funding- pre-clinical- clinical and commercial milestones of $266.9M along with royalties on sales. Bayer to gain exclusive access to novel molecules from Curadev- designed to inhibit the STING pathway
• The alliance focusses to discover new therapies targeting lung diseases- CV diseases and other inflammatory diseases. The collaboration will optimize and advance the novel molecules generated during the collaboration into clinical development
• STING antagonists offer the potential for new treatments as STING plays a role in activating the innate immune system in auto-inflammatory diseases

Click here ­to­ read full press release/ article | Ref: Bayer | Image: Latifundist